Evidence map›Paper›PMID 33682815›Full record

ArticleActa bio-medica : Atenei Parmensis2021

Dermatological manifestations during COVID-19 infection: a case series and discussion on the problem of differential diagnosis.

Erminia Ridolo, Francesco Pucciarini, Alessandro Barone, Antonio Nouvenne, Tiziana Meschi, Silvia Peveri, Cristoforo Incorvaia

Open access · greenAbstract readCase Reports
In one paragraph

Article in Acta bio-medica : Atenei Parmensis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Erminia RidoloMedicine and Surgery Department, Allergy and Clinical Immunology, University of Parma, Parma, Italy. erminia.ridolo@unipr.it.
Francesco PucciariniMedicine and Surgery Department, Allergy and Clinical Immunology, University of Parma, Parma, Italy. f.pucciarini@gmail.com.
Alessandro Barone1Medicine and Surgery Department, Allergy and Clinical Immunology, University of Parma, Parma, Italy. ale_barone04@tiscali.it.
Antonio NouvenneMedicine and Surgery Department, Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, University of Parma, Parma, Italy. ANouvenne@ao.pr.it.
Tiziana MeschiMedicine and Surgery Department, Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, University of Parma, Parma, Italy. tiziana.meschi@unipr.it.
Silvia PeveriDepartmental Unit of Allergology, Guglielmo da Saliceto Hospital, Piacenza, Italy. s.peveri@ausl.pc.it.
Cristoforo IncorvaiaCardiac/Pulmonary Rehabilitation, ASST Pini-CTO, Milan, Italy. cristoforo.incorvaia@gmail.com.
University of Parma · ITOspedale di Parma · ITGuglielmo da Saliceto Hospital · ITIstituto Ortopedico Gaetano Pini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On March 11, 2019 the World Health Organization (WHO) declared Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, as a pandemic. As of 15/01/2021, more than ninety million cases of infections have been confirmed, with almost two million related deaths. SARS-CoV-2 causes bilateral interstitial pneumonia, which can responsible of respiratory failure in the most severe cases, but the virus has also a wide range of other manifestations, including gastrointestinal, cardiovascular, neurological, and cutaneous signs and symptoms. Cutaneous manifestations are an important matter of study for allergy specialists, as they can be specific signs of the infection, but also manifestations of adverse reactions to the medical therapy in use. In this case series, we report four different cases of dermatological manifestations in COVID patients, two in hospitalised patients and two in patients with mild disease, treated at home. The first case reported is a woman, who develops urticaria while being treated at home with mild COVID-infection; the second and the third one case reported are drug- hypersensivity reaction to remdesevir and low molecular weight heparin. The last case reported is a man with mild covid with vasculitic sacral lesions. Key words: COVID pandemic, SARS-CoV-2, dermatological manifestation in covid infections, remdesevir hypersensitivity, covid and urticaria, covid and vasculitic lesions.

Indexed as

SARS-CoV-2Adenosine MonophosphateAlanineCOVID-19COVID-19 Drug TreatmentDiagnosis, DifferentialDrug HypersensitivityFemaleHumansMaleMiddle AgedSkin DiseasesAdenosine MonophosphateAlanineremdesivir

Identifiers

PMID33682815
PMCPMC7975949
OpenAlexW3134548114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.